How FGF signaling affects lung development and alveolar formation
Regulation of primary and secondary alveologenesis by FGF signaling pathways
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-11028111
This study is looking at how certain signals in the body help form tiny air sacs in the lungs, which are really important for breathing, especially in premature babies who might have trouble with their lungs due to a condition called bronchopulmonary dysplasia (BPD), and it hopes to find new ways to help these babies breathe better.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-11028111 on ClinicalTrials.gov |
What this research studies
This research investigates the role of FGF signaling pathways in the development of alveoli, which are crucial for effective lung function. It focuses on understanding how these pathways influence the formation of alveolar structures during lung development, particularly in the context of bronchopulmonary dysplasia (BPD), a condition that affects premature infants. By studying the cellular and molecular mechanisms involved, the research aims to identify potential therapeutic targets to enhance lung development and improve outcomes for affected infants.
Who could benefit from this research
Good fit: Ideal candidates for this research are premature infants diagnosed with bronchopulmonary dysplasia who are experiencing impaired lung development.
Not a fit: Patients who are not premature or do not have bronchopulmonary dysplasia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that promote lung development in infants with bronchopulmonary dysplasia, potentially reducing long-term respiratory issues.
How similar studies have performed: Previous research has shown promising results in understanding lung development mechanisms, but this specific approach focusing on FGF signaling pathways is relatively novel.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ORNITZ, DAVID M — WASHINGTON UNIVERSITY
- Study coordinator: ORNITZ, DAVID M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.